Xenon Pharmaceuticals Inc. Stock News

VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. Stifel 2025 Healthcare ...

Xenon Pharmaceuticals Inc. ( XENE ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Colleen Alabiso Ian Mortimer - President, CEO, Principal Accounting Officer & Director Christopher Kenney - Chief Medical Officer Thomas Kelly - Chief Financial Officer Darren Cline - Chief Commercial Officer and Member of Executive Team Conference Call Participants Paul Matteis - Stifel,...

– Phase 3 X-TOLE2 FOS topline data on track to read out early 2026 with patient randomization complete  – Phase 3 X-NOVA2 and X-NOVA3 studies in MDD & Phase 3 X-CEED study in BPD continuing to recruit – Phase 1 Nav1.7 & Kv7 studies underway – Tucker Kelly appointed as Chief Financial Officer, bringing extensive strategic commercial finance experience in anticipation of the azetukalner launch – ...

VANCOUVER, British Columbia and BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced it will report its third quarter 2025 financial results and provide a business update after...

Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience Mr. Kelly is a proven strategic CFO with significant financial, operational and commercialization leadership experience

VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of ...

Xenon Pharmaceuticals Inc. - Special Call Company Participants Ian Mortimer - Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Officer & Director James Empfield - Executive Vice President of Drug Discovery JP Gilbert Christopher Kenney - Chief Medical Officer Presentation Ian Mortimer Interim CFO, President, CEO, Principal Financial Officer, Principal Accounting Of...

VANCOUVER, British Columbia and BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its early-stage programs target...